Maira Campos is an Oncology physician affiliated with University of California, Los Angeles. OpenAlex indexes 22 publications with 875 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
540 W Pueblo St
Santa Barbara, CA 931054230
Telephone
805-879-0670Provider last certified this registry record 12 Aug 2022.
Clinical trials
1 registered study on ClinicalTrials.gov matched to this name. Itemized trial rows, roles and sponsors are part of the full profile. Why? →
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20252 payments
- Lilly USA, LLCProgram year20251 payment
- Daiichi Sankyo Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.3%PD-1 inhibitor33.2%Pembrolizumab100%Part B, office-administered≥15 patientsAromatase Inhibitor1.5%Letrozole71%Anastrozole18%Exemestane11%Part D≥125 patients+ 7 more classes in this area
Blood & clotting
29.1%Erythropoiesis-stimulating Agent29%Darbepoetin alfa100%Part B, office-administered≥13 patientsFactor Xa inhibitor0.2%Eliquis100%Part D≥15 patientsMetabolism & gastrointestinal
26.3%Other antiemetics21.4%Fosaprepitant100%Part B, office-administered≥21 patientsSerotonin-3 Receptor Antagonist4.6%Palonosetron hcl63%Granisetron hydrochloride32%Ondansetron Hcl3%Ondansetron Odt3%Part D + Part B≥33 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Iron Deficiency Thrombocytopenia: A Case Report and Review of the Literature
Journal of Clinical Case Reports
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Dennis Slamon, MD
University of California, Los Angeles
Beth Karlan, MD
University of California, Los Angeles
Richard Casaburi, MD
University of California, Los Angeles
Robert Modlin, MD
University of California, Los Angeles
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”